Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli] |
French
|
Hémoglobinurie nocturne paroxystique [Marchiafava-Micheli] |
| Level | Code | Title | |
|---|---|---|---|
| 1 | III | Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | |
| 2 | D55-D59 | Haemolytic anaemias | |
| 3 | D59 | Acquired haemolytic anaemia | |
| 4 | D59.5 | Paroxysmal nocturnal haemoglobinuria [Marchiafava-Micheli] |
| Active Ingredient | Description | |
|---|---|---|
| Eculizumab |
Eculizumab is a monoclonal antibody, a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes. |
|
| Ravulizumab |
Ravulizumab is a monoclonal antibody IgG2/4K that specifically binds to the complement protein C5, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the C5b-9. Ravulizumab preserves the early components of complement activation that are essential for opsonisation of microorganisms and clearance of immune complexes. It is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH). |
